Skip to main content

SARS-CoV-2 Vaccine Does Not Increase New-Onset Seizure Risk

Medically reviewed by Carmen Pope, BPharm. Last updated on April 30, 2024.

By Lori Solomon HealthDay Reporter

TUESDAY, April 30, 2024 -- There is no risk for new-onset seizure incidence for individuals receiving a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine versus placebo, according to a review published online April 29 in JAMA Neurology.

Ali Rafati, M.D., from Iran University of Medical Sciences in Tehran, and colleagues conducted a systematic literature review to identify studies examining seizure incidence among SARS-CoV-2 vaccine recipients versus those receiving placebo.

Based on six randomized clinical trials (63,521 vaccine and 54,919 placebo recipients), the researchers found that during a 28-day follow-up after injection, there was no statistically significant difference between the groups (nine events in vaccine recipients [0.014 percent] and one event in placebo recipients [0.002 percent]; odds ratio, 2.70; 95 percent confidence interval, 0.76 to 9.57; P = 0.12). Similarly, when examining the entire blinded-phase period after injection (median >43 days), there were no significant differences identified for incident new-onset seizure (0.03 percent in vaccine recipients and 0.012 percent in placebo recipients; odds ratio, 2.31; 95 percent confidence interval, 0.86 to 3.23; P > 0.99).

"Since the inflammatory response induced by SARS-CoV-2 infection is probably more prolonged and severe than the SARS-CoV-2 vaccines, the adverse events would be more prevalent and critical; however, it has to be confirmed by future studies," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Mortality Higher for COVID-19 Hospitalization Than for Flu in 2023/2024 Season

WEDNESDAY, May 22, 2024 -- In fall/winter 2023/2024, the risk for death in patients hospitalized for COVID-19 was greater than the risk for death in patients hospitalized for...

Global Life Expectancy, Disease Burden Set to Keep Improving

WEDNESDAY, May 22, 2024 -- Life expectancy and age-standardized disease burden are expected to continue improving between 2022 and 2050, according to the Global Burden of Disease...

Preparedness for HPAI A(H5N1) Virus Varies Across Jurisdictions

TUESDAY, May 21, 2024 -- Variation is seen in preparedness and response to highly pathogenic avian influenza (HPAI) A(H5N1) viruses, according to a research letter published...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.